Lodamine is the first broad–spectrum angiogenesis inhibitor for oral use
Unlike currently available vascular growth inhibitors, such as Avastin, most of which act only on one of the angiogenesis factors, for example, vascular endothelial growth factor (VEGF) and are approved only for the treatment of a small number of specific types of cancer, Lodamine prevents capillary growth under the action of all tested angiogenesis stimulants.
03.07.2008